TGFB1 and idiopathic pulmonary fibrosis: We show that these inhibitors can reduce matrix deposition and reverse the myofibroblast phenotype in IPF via preventing the activation of TGFβ1, reducing myofibroblast biomarkers and inhibiting excessive matrix protein deposition.